Endocrine therapy in epithelial ovarian cancer

File Description SizeFormat 
Endocrine Therapy in Ovarian Cancer submitted version.pdfAccepted version641.62 kBAdobe PDFView/Open
Title: Endocrine therapy in epithelial ovarian cancer
Authors: Langdon, SP
Gourley, C
Gabra, H
Stanley, B
Item Type: Journal Article
Abstract: INTRODUCTION: The estrogen receptor (ER) is expressed at high levels in many epithelial ovarian cancers (EOC) and represents a potential target for endocrine therapy. Both anti-estrogens and aromatase inhibitors have been evaluated in phase II clinical trials. Areas covered: We present an overview of the phase II and phase III trials of anti-estrogens (tamoxifen and fulvestrant) and aromatase inhibitors (letrozole, anastrazole and exemestane) undertaken in epithelial ovarian cancer identified through a Pubmed search. We describe predictive biomarkers that are being investigated to identify responsive cancers. Expert commentary: The efficacy of endocrine therapy in epithelial ovarian cancer is likely to be confined to histological subtypes with the highest ER expression while low grade serous ovarian cancer appears to be one subgroup with good sensitivity to these agents. The low toxicity profile of these agents is favourable although their use is unlicensed and the optimal setting undefined. Prospective clinical trials of endocrine agents in the early relapse and maintenance settings are urgently required to establish their definitive role in the management of epithelial ovarian cancer.
Issue Date: 14-Dec-2016
Date of Acceptance: 12-Dec-2016
URI: http://hdl.handle.net/10044/1/44228
DOI: http://dx.doi.org/10.1080/14737140.2017.1272414
ISSN: 1744-8328
Publisher: Taylor & Francis
Start Page: 109
End Page: 117
Journal / Book Title: Expert Review of Anticancer Therapy
Volume: 17
Issue: 2
Copyright Statement: © 2016 Taylor & Francis. This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Anticancer Therapy on 14 Dec 2016, available online: http://www.tandfonline.com/10.1080/14737140.2017.1272414
Keywords: Ovarian cancer
anastrazole
estrogen receptor
fulvestrant
letrozole
tamoxifen
Oncology & Carcinogenesis
1112 Oncology And Carcinogenesis
Publication Status: Published
Conference Place: England
Appears in Collections:Division of Surgery
Division of Cancer
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commonsx